IGI Laboratories Announces the Submission of Fifth ANDABUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to five. IGI President and CEO Charlie Moore commented, “We are excited to have one additional ANDA filing for 2011. We now have five ANDAs on file with the US FDA, and we are poised to deliver a strong product development performance in 2012. ANDAs are the key to the future at IGI and our development ... Thursday, 29 December 2011 Read more |
IGI Laboratories and Neostrata Company, Inc. Extend Turnkey Supply Agreement(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, and NeoStrata Company, Inc., (www.neostrata.com) headquartered in Princeton, NJ, announced a three-year extension to their Turnkey Manufacturing Services agreement. Under the terms of the extension, IGI Laboratories, Inc. (IGI) will continue supplying NeoStrata Company, Inc. (NeoStrata) with fully-packaged, market-ready skin care products that will be available worldwide through consumer outlets, physicians’ offices and spas.“Our partnership with NeoStrata continues to flourish” commented IGI President and CEO Charlie Moore “We are pleased to secure this relationship for the next three years. We are committed to ... Thursday, 22 December 2011 Read more |
IGI Laboratories and Neostrata Company, Inc. Extend Turnkey Supply Agreement(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, and NeoStrata Company, Inc., (www.neostrata.com) headquartered in Princeton, NJ, announced a three-year extension to their Turnkey Manufacturing Services agreement. Under the terms of the extension, IGI Laboratories, Inc. (IGI) will continue supplying NeoStrata Company, Inc. (NeoStrata) with fully-packaged, market-ready skin care products that will be available worldwide through consumer outlets, physicians’ offices and spas.“Our partnership with NeoStrata continues to flourish” commented IGI President and CEO Charlie Moore “We are pleased to secure this relationship for the next three years. We are committed to ... Thursday, 22 December 2011 Read more |
IGI Laboratories, Inc. and Medimetriks Pharmaceuticals, Inc. Enter Long Term Strategic PartnershipBUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has entered into a long term strategic partnership with Medimetriks Pharmaceuticals, Inc. This strategic partnership designates IGI Laboratories, Inc. (IGI) as the developer and manufacturer of a family of prescription topical drug products owned by Medimetriks Pharmaceuticals, Inc. (Medimetriks). In addition, as part of this long term relationship, Medimetriks has appointed IGI as Medimetriks’ authorized generic distributor of certain products in this line. Medimetriks expects to launch its new line of prescription topical brands during the ... Thursday, 8 December 2011 Read more |
IGI Laboratories, Inc. and Medimetriks Pharmaceuticals, Inc. Enter Long Term Strategic PartnershipBUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has entered into a long term strategic partnership with Medimetriks Pharmaceuticals, Inc. This strategic partnership designates IGI Laboratories, Inc. (IGI) as the developer and manufacturer of a family of prescription topical drug products owned by Medimetriks Pharmaceuticals, Inc. (Medimetriks). In addition, as part of this long term relationship, Medimetriks has appointed IGI as Medimetriks’ authorized generic distributor of certain products in this line. Medimetriks expects to launch its new line of prescription topical brands during the ... Thursday, 8 December 2011 Read more |
IGI Laboratories Announces the Submission of Two More ANDAs(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.IGI President and CEO Charlie Moore commented “We are excited to announce that we successfully developed and submitted two more ANDAs. Our experienced team of development professionals is focused on our mission, to build a portfolio of topical drug products for IGI.” The development of ANDA products has successfully been integrated into the company’s ongoing contract services ... Friday, 2 December 2011 Read more |
IGI Laboratories Announces the Submission of Two More ANDAs(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.IGI President and CEO Charlie Moore commented “We are excited to announce that we successfully developed and submitted two more ANDAs. Our experienced team of development professionals is focused on our mission, to build a portfolio of topical drug products for IGI.” The development of ANDA products has successfully been integrated into the company’s ongoing contract services ... Friday, 2 December 2011 Read more |
IGI Laboratories, Inc. Ranked Number 23 Fastest Growing Company in the Greater Philadelphia RegionAttributes 133% Percent Revenue Growth to a commitment to excellence. Buena, New Jersey, October 19, 2011 — IGI Laboratories, Inc. today announced it ranked 23rd on Deloitte’s 2011 Greater Philadelphia Fast 50 ranking of the 50 fastest growing technology, media, telecommunications, life sciences and clean technology companies in the Greater Philadelphia region. IGI Laboratories grew 133 percent during this period. IGI’s chief executive officer, Charlie Moore credits a dedicated workforce and strong leadership with the company’s 133% revenue growth. He said, “At IGI we have a clear vision for success and a talented team driving us forward.” “IGI Laboratories, like all 2011 Greater ... Wednesday, 9 November 2011 Read more |
Welcome to the IGI Laboratories company news section.
Please choose an article from the header above, you can use the navigation arrows to navigate through previously posted news articles.
*Industry News displayed is received from the FDA News website. All rights reserved.